
    
      This Phase 3 study patients will be randomized in a 1:1 ratio to treatment with relacorilant
      (active drug) or placebo. Patients will receive relacorilant or placebo for 22 weeks.
      Patients who complete the study may also be eligible to roll over into an extension study.
    
  